Palisade Bio, Inc. (PALI)
Palisade Bio develops oral drug candidates for inflammatory bowel disease, led by PALI-2108 for ulcerative colitis and Crohn's disease. It last closed at $1.01 on Nov 17, down 1.94% on the day. The average 12-month price target from 3 analysts is $9.00 (+791.1% from the last close), with a high of $16.00 and a low of $5.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Key Stats
Last 12 monthsNot reported for this period.
From PALI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on PALI in the past 90 days. The average target is $9.00, with a high of $16.00 and a low of $5.00, compared with the last close of $1.01.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 11 | Piper Sandler | Maintained | Buy | $16 |
| Nov 11 | HC Wainwright & Co. | Target lowered | Buy | $7 → $5 |
| Oct 13 | HC Wainwright & Co. | Reiterated | Buy | $7 |
| Oct 9 | Raymond James | Initiated | Buy | $6 |
| Jul 23 | Oppenheimer | Initiated | Buy | $8 |
Technical Analysis
The stock is 18% below its 20 day and 42% below its 50 day average. It is 80% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the 52 week low at $0.99, and the nearest resistance the Pivot R1 at $1.03.
| RSI (14) | 32.38 | Weak, oversold below 30 | Neutral |
| MACD | -0.11 | Below its signal line | Bearish |
| Stochastic | 10.0 | Near the bottom of its range | Oversold |
| ADX (14) | 40.2 | Strong downtrend | |
| Williams %R | -93.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -167.0 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −17.9% | Change over 10 sessions | Bearish |
| ATR (14) | $0.10 | Typical daily range, 9.5% of price |
| RSI (14) | 30.61 | Weak, oversold below 30 | Neutral |
| MACD | -0.21 | Below its signal line | Bearish |
| Stochastic | 3.1 | Near the bottom of its range | Oversold |
| ADX (14) | 22.8 | Weak trend | |
| Williams %R | -98.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -128.7 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −51.0% | Change over 10 sessions | Bearish |
| ATR (14) | $0.26 | Typical daily range, 25.3% of price |
What happened before
See how PALI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PALI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in PALI in the last 90 days.
PALI Institutional Ownership
Full report →- ●57 buying vs 53 selling
- ▲Held by funds +2.5 pts
- ▼Funds holding -8
- ▼Superinvestors: 1 added, 3 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 116 | 124 | −6.5% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | 99.2% | 96.7% | +2.5 pts |
| New / increased | 17 / 40 | 49 / 33 | −30.5% |
| Reduced / sold out | 28 / 25 | 24 / 21 | +17.8% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PALI is in one of them and how their past PALI trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PALI in an article yet. Here's the latest on the wider market.
About Palisade Bio
Palisade Bio is a biopharmaceutical company based in Carlsbad, California, that is developing oral medicines for inflammatory bowel disease. Its lead candidate, PALI-2108, is a pill taken once a day that stays inactive until it reaches the lower intestine, where gut bacteria convert it into an active drug at sites of inflammation. The company is testing the candidate in people with ulcerative colitis and Crohn's disease. Its candidates are still in clinical testing and are not yet on the market.
- Headquarters
- Carlsbad, CA



